Firm to Acquire CBD Products Designer
Source: Streetwise Reports  (11/18/19)
The deal encompasses all of the company's brands, formulations and processes. More >

Karuna Shares Jump 375% Higher on Phase 2 Acute Psychosis Treatment Trial Data
Source: Streetwise Reports  (11/18/19)
Shares of Karuna Therapeutics, which completed an IPO in July 2019, soared more than 375% higher today after the firm reported that its KarXT met primary endpoint in a phase 2 clinical trial of acute psychosis in patients with schizophrenia. More >

Sales of Antibiotic Alternative for Livestock Feed Accelerate in Asia
Source: Streetwise Reports  (11/15/19)
With antibiotic resistance a major health issue, the search is on for effective alternatives to replace antibiotics in livestock feed to promote growth. More >

Plus Therapeutics Shares Trade Higher on Q3 Earnings and Business Restructuring
Source: Streetwise Reports  (11/15/19)
Plus Therapeutics shares opened 25% higher today after the firm reported Q3/19 financial and business results. In the most recent quarter, the company completed the change of its name, relocated its headquarters to Austin, and raised $15 million for R&D and working capital. More >

Exicure's Collaboration with Allergan on Treating Hair Loss Disorders Sends Shares Higher
Source: Streetwise Reports  (11/14/19)
Shares of Exicure Inc. opened 30% higher today after the firm reported that it entered into a collaboration agreement with Allergan to discover and develop SNA-based treatments for hair loss disorders. The terms of the deal provide for a $25 million upfront payment to Exicure with the potential to grow to $750 million. More >

Reliq Re-establishes Itself as Community Care Technology Leader Amidst Sweeping Federal Medicare/Medicaid Changes
Source: Knox Henderson for Streetwise Reports  (11/13/19)
A shift in the industry leads to big new contracts and parabolic stock performance for this small cap. More >

Biopharma Presents Data on Alcoholic Hepatitis Therapeutic at Liver Meeting
Source: Streetwise Reports  (11/13/19)
The company intends to follow up in 2020 with a Phase 2b clinical trial. More >

FDA Approval of Peanut Allergy Treatment Expected Next Year
Source: Streetwise Reports  (11/13/19)
The current status, catalysts and outlook for the immunotherapy are discussed in a ROTH Capital Partners report. More >

Clinical Trial Results for Alcoholic Hepatitis Drug Delivered in Webcast
Source: Streetwise Reports  (11/13/19)
The online presentation coincides with The Liver Meeting 2019, at which data also are shared. More >

Electromed Earnings Spark a 25% Increase in Its Share Price
Source: Streetwise Reports  (11/13/19)
Shares of SmartVest maker Electromed traded 25% higher today after the firm reported Q1/20 earnings. The firm's shares set a 52-week high price after reporting a 14.1% increase in year-over-year quarterly revenue and a six-fold increase in net income per share. More >

Seachange in Mexico on Cannabis Could Benefit This Small Cap
Source: Clive Maund for Streetwise Reports  (11/13/19)
Technical analyst Clive Maund highlights a small-cap that may be poised to benefit from the recent Mexican Supreme Court decision on cannabis. More >

Imagin Medical Poised for Breakout with Bladder Cancer Detection Device
Source: Knox Henderson for Streetwise Reports  (11/12/19)
A new advancement in bladder-related endoscopic surgery is endorsed and de-risked. More >

Castle Biosciences Shares Storm Higher After Quadrupling Q3 YoY Revenue
Source: Streetwise Reports  (11/12/19)
Shares of melanoma and other skin cancers diagnostic firm Castle Biosciences Inc. traded more than 15% higher today after the firm announced Q3/19 financial and operational results. More >

Iovance Biotherapeutics Shares Rise 12% on Updated Phase 2 Melanoma Study Results
Source: Streetwise Reports  (11/8/19)
Shares of Iovance Biotherapeutics traded 12% higher today after the firm reported updated clinical data from its phase 2 lifileucel metastatic melanoma trial. More >

Dexcom Posts 49% YoY Revenue Growth, Sending Shares to 52-Week High
Source: Streetwise Reports  (11/7/19)
Glucose monitoring systems developer Dexcom's shares traded 30% higher today after releasing Q3/19 earnings and raising full-year 2019 guidance. More >

Could There Finally Be an Effective Treatment for Alzheimer's Disease?
Source: Streetwise Reports  (11/6/19)
ProMIS' preclinical treatment could possibly outshine Biogen's candidate. More >

Aquestive Therapeutics Shares Up on Pipeline Update and Raised Full-Year 2019 Guidance
Source: Streetwise Reports  (11/6/19)
Aquestive Therapeutics shares traded 20% higher today after the firm reported Q3/19 earnings and raised its FY/19 guidance. The firm states it expects to complete its NDA for Libervant buccal film near the end of this month. More >

Fulgent Genetics Hits 52-Week High After Posting 84% Q3 Revenue Increase
Source: Streetwise Reports  (11/5/19)
Fulgent Genetics shares traded more than 40% higher today after the company reported record revenue in Q3/19. The firm noted that it completed a record 20,697 billable tests in Q3/19, up 272% over the same period last year. More >

RedHill Biopharma Shares Rise 10% After Receiving FDA Approval for H. Pylori Treatment Drug Talicia
Source: Streetwise Reports  (11/4/19)
Shares of RedHill Biopharma Ltd. traded more than 10% higher today after the firm announced that the FDA has approved its Talicia delayed-release capsules for the treatment of H. pylori infection in adults. The firm plans to commence distribution by its U.S. sales force in Q1/20. More >

Vancouver Firm Receives Cannabis Flower Sales License, First Order
Source: Streetwise Reports  (11/3/19)
Both of these events are significant achievements for the company. More >

Canadian Tech Firm Lands U.S. Medical Case Management Firm as Client
Source: Streetwise Reports  (11/3/19)
This new partner seeks to employ the company's telemedicine/mobile health system. More >

BeiGene Shares Up 35% on Amgen's $2.7 Billion Investment and China Partnership
Source: Streetwise Reports  (11/1/19)
Shares of BeiGene Ltd. traded 35% higher today to a new a 52-week intraday high after announcing a commercialization agreement for of XGEVA (denosumab), KYPROLIS (carfilzomib), and BLINCYTO (blinatumomab) with Amgen Inc. in China. As part of the partnership, Amgen will invest $2.7 billion in BeiGene for 20.5% equity ownership. More >

Tech Firm Partners With Pharmacy, Diabetes Management Entities
Source: Streetwise Reports  (10/31/19)
The Canadian company will provide its remote patient monitoring and chronic care management software solutions to these two U.S. enterprises. More >

Navidea Shares Jump 60% on Phase 2b Rheumatoid Arthritis Trial Results
Source: Streetwise Reports  (10/29/19)
Shares of Navidea Biopharmaceuticals traded 60% higher today on extremely high relative volume after the firm released data from its Phase 2b Rheumatoid Arthritis Tc 99m Tilmanocept Planar Imaging study. More >

New Data Could Drive Use of Pancreatic Cancer Early Detection Test
Source: Streetwise Reports  (10/29/19)
The recent results and their implications are provided in an H.C. Wainwright & Co. report. More >